Assembly Biosciences Q2 revenue rises from Gilead collaboration

Assembly Biosciences

06/08/2025 21:38

Overview

Assembly Biosciences Q2 revenue from Gilead collaboration rises to $9.6 mln

Net loss narrows to $10.2 mln from $11.2 mln year-over-year

Outlook

Assembly Bio projects cash to fund operations into mid-2026

Result Drivers

GILEAD COLLABORATION - Increased revenue from expanded research activities with Gilead

COSTS EASE - R&D expenses decrease largely due to a decrease in spending on ABI-6250 trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$1.33
Q2 Net Income
-$10.20 mln
Q2 Basic EPS
-$1.33
Q2 Income From Operations
-$11.09 mln
Q2 Operating Expenses
$20.72 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Assembly Biosciences Inc is $31.00, about 39.2% above its August 5 closing price of $18.86

Press Release: ID:nGNX9fY5cQ

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)